Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 11/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | ITK | Q08881 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PPIA | P62937 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6502166 | 0.86 | MAPT (0.46) | ITKMEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL6504829 | 0.82 | SCN9A (0.53) | PTGER1ITKPPIA | |
| SCHEMBL6500313 | 0.78 | ITK (0.47) | ITKMEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL6506313 | 0.77 | ITK (0.44) | ITKNOTUMMEN1KMT2ANPC1 | |
| SCHEMBL6502246 | 0.77 | ITK (0.44) | ITKNPC1ALDH1A1 | |
| SCHEMBL6467605 | 0.77 | ITK (0.44) | ITKMEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL6467554 | 0.77 | KMT2A (0.46) | ITKMEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL6499099 | 0.77 | ITK (0.42) | ITKMEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL6507055 | 0.76 | ITK (0.53) | ITKNOTUMNPC1ALDH1A1 | |
| SCHEMBL6500141 | 0.75 | ITK (0.44) | ITKNPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | PHARMACIA AND UPJOHN COMPANY LLC | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | IL4, ARG2, CASP4 | PTGER1 749/4885FFAR4 452/4885ITK 4236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.